MedPath

University of Salerno

University of Salerno logo
🇮🇹Italy
Ownership
Private
Established
1968-01-01
Employees
1K
Market Cap
-
Website
http://www.unisa.it

Clinical Trials

16

Active:0
Completed:5

Trial Phases

3 Phases

Phase 3:1
Phase 4:2
Not Applicable:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials

Not Applicable
4 (57.1%)
Phase 4
2 (28.6%)
Phase 3
1 (14.3%)

Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure

Not yet recruiting
Conditions
Heart Failure
First Posted Date
2025-06-17
Last Posted Date
2025-06-22
Lead Sponsor
University of Salerno
Target Recruit Count
205
Registration Number
NCT07023536

AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices

Not yet recruiting
Conditions
Chronic Heart Failure
Cardiovascular Diseases
Heart Failure With Reduced Ejection Fraction (HFrEF)
Heart Failure With Preserved Ejection Fraction (HFPEF)
Congestive Heart Failure Chronic
First Posted Date
2025-04-03
Last Posted Date
2025-04-03
Lead Sponsor
University of Salerno
Target Recruit Count
205
Registration Number
NCT06909682

Efficacy and Safety of Transcranial dIrect Current stiMulation in Multiple System Atrophy-Cerebellar Variant

Not Applicable
Recruiting
Conditions
Multiple System Atrophy - Cerebellar Subtype (MSA-C)
First Posted Date
2025-02-11
Last Posted Date
2025-04-16
Lead Sponsor
University of Salerno
Target Recruit Count
30
Registration Number
NCT06821256
Locations
🇮🇹

Centro per le Malattie Neurodegenerative (CEMAND) Dipartimento di Medicina e chirurgia, Sezione Neuroscienze, Università di Salerno, Salerno, Sa, Italy

Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis

Recruiting
Conditions
Low Flow, Low Gradient Aortic Stenosis
First Posted Date
2024-09-10
Last Posted Date
2024-09-19
Lead Sponsor
University of Salerno
Target Recruit Count
1500
Registration Number
NCT06589063
Locations
🇮🇹

University of Salerno, Salerno, Italy

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients

Phase 4
Not yet recruiting
Conditions
Lipid Metabolism Disorders
Statin Adverse Reaction
Cardiovascular Diseases
Dyslipidemias
Interventions
Drug: Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe
Drug: Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
First Posted Date
2024-04-24
Last Posted Date
2024-04-24
Lead Sponsor
University of Salerno
Target Recruit Count
130
Registration Number
NCT06381947
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.